Published in Nat Rev Cardiol on August 18, 2015
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor (SWAP3) | NCT02016170
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej (2015) 0.84
Newer P2Y12 Inhibitors: How Does the Interventional Cardiologist Choose? J Am Heart Assoc (2016) 0.75
Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol (2017) 0.75
Nanotechnology in diagnosis and treatment of coronary artery disease. Nanomedicine (Lond) (2016) 0.75
Single or dual antiplatelet therapy after PCI. Nat Rev Cardiol (2017) 0.75
Purinergic Signalling: Therapeutic Developments. Front Pharmacol (2017) 0.75
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
Platelet activation and atherothrombosis. N Engl J Med (2007) 6.18
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med (2012) 4.37
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation (2009) 2.84
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation (2010) 2.46
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2014) 2.30
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol (2014) 2.12
Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome. Circ Cardiovasc Interv (2014) 1.97
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol (2013) 1.94
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther (2009) 1.73
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol (2010) 1.66
Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial. Circ Cardiovasc Interv (2012) 1.54
Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost (2005) 1.49
Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc Interv (2013) 1.48
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA (2012) 1.43
ADP receptors of platelets and their inhibition. Thromb Haemost (2001) 1.43
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost (2012) 1.42
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol (2009) 1.41
Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int J Cardiol (2014) 1.39
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol (2010) 1.26
The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol (2000) 1.26
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol (2012) 1.20
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv (2012) 1.14
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost (2009) 1.12
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv (2012) 1.11
Basic principles of platelet biology and clinical implications. Circ J (2010) 1.09
Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol (2014) 1.08
Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des (2006) 1.06
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J (2011) 1.05
Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J (2012) 1.04
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J (2009) 1.03
Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res (2007) 1.03
The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs (2012) 0.92
Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol (2012) 0.92
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. J Am Coll Cardiol (2012) 0.91
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis (2012) 0.90
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets (2008) 0.88
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Catheter Cardiovasc Interv (2012) 0.87
In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care (2014) 0.86
The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J (2011) 0.86
Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J Am Heart Assoc (2014) 0.86
Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study. Platelets (2012) 0.84
Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. Int J Cardiol (2012) 0.84
Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy. Circulation (2014) 0.82
Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. Eur Heart J Acute Cardiovasc Care (2015) 0.82
The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost (2008) 0.81
Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). J Am Coll Cardiol (2013) 0.81
Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther (2013) 0.81
Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. Eur Heart J Acute Cardiovasc Care (2014) 0.81
Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv (2014) 0.80
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. JACC Cardiovasc Interv (2014) 0.80
Platelet function testing in contemporary clinical and interventional practice. Curr Treat Options Cardiovasc Med (2014) 0.80
MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry. Eur Heart J Acute Cardiovasc Care (2014) 0.80
In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv (2014) 0.80
Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified. Circulation (2014) 0.80
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am Heart J (2014) 0.79
Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis (2015) 0.79
Switching from prasugrel to clopidogrel: navigating in unknown waters. JACC Cardiovasc Interv (2013) 0.79
Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Thromb Res (2012) 0.79
In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J (2013) 0.79
Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions. Am J Health Syst Pharm (2010) 0.78
Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol (2010) 0.78
Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol (2012) 0.78
Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. Circ Cardiovasc Interv (2015) 0.77
A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study. Thromb Haemost (2016) 0.76
A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. PLoS One (2014) 0.76
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. Int J Cardiol (2013) 0.76
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thromb Haemost (2014) 0.76
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. Circ Cardiovasc Interv (2013) 0.76
Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience. J Thromb Thrombolysis (2014) 0.76
Switching from clopidogrel to prasugrel in patients having coronary stent implantation. J Thromb Thrombolysis (2014) 0.76
Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndrome. Int J Cardiol (2014) 0.76
Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. Thromb Haemost (2013) 0.76
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. BMC Cardiovasc Disord (2014) 0.76
Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. J Thromb Thrombolysis (2015) 0.76
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity. J Interv Cardiol (2014) 0.75
Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity. Int J Cardiol (2014) 0.75
Platelet function profiles in patients with diabetes mellitus. J Cardiovasc Transl Res (2013) 0.78
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. Future Cardiol (2015) 0.76
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur Heart J (2016) 0.75
Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease. Future Cardiol (2012) 0.75